Lung Adenocarcinoma

Delighted to share our latest paper on the mechanistic modeling of disease progression in EGFR-mutant lung adenocarcinoma: https://t.co/dsB0zfo9rc A special thanks to @MDuruisseaux & to all co-authors from @novadiscovery , @JanssenFRA. (@Claudio_MonT_s)

The comparison of tumor mutational burden (TMB) in patients of early and late stage lung adenocarcinoma in China - Zhang et al. Abstract 8520 #ASCO18 https://t.co/FQqHhz2PHR #PrecisionMedicine #ImmunoOnc #lcsm (@mtmdphd)

Don’t forget lung adenocarinoma (@JennyCarlisleMD)

BRAF mutation Seen in melanoma (40-60%) papillary thyroid carcinoma (45%), colonic adenocarcinoma (10-15%), hairy cell leukemia (~100%) lung adenocarcinoma, epithelioid glioblastoma, and hematologic malignancies, including hairy cell leukemia, LCH, ECD (@Sthanu5)

ALK Mutation is present in 2.81% of @AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence. https://t.co/xqPTiPcovZ @ALKPositiveinc… https://t.co/KcF0yqWyPP (@4baseCare)

Lactate in the tumor microenvironment is just bad news for tumor immune surveillance. Out in @Cancer_Cell from @MDAndersonNews & collaborators: MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma https://t.co/RzdGGZ4RmH (@Aiims1742)

I have a case i would like to share and I need assistance. 70 years old non smoker female with stage IV NSCLC ( adenocarcinoma) EGFR exon 20 ins by NGS. What’s the recommendation for as regard 1st line ? @APassaroMD 🙏 (@omarmokhtar89)

Second Hand Smoking and Air pollution are among the major causes of Lung cancer in nonsmokers. The incidence of lung cancer especially adenocarcinoma is on the rise globally. The major risk factors are exposure to second hand smoke, indoor and outdoor pollution @sujithonco (@ApolloProton)

👩‍🔬Discover how TTA-A2 enhances the anticancer effect and combats chemoresistance in lung adenocarcinoma cells. @CharuAggarwalMD @DrewMoghanaki @lcrf_org @CRUKLungCentre @BenjaminBesseMD @MMarmarelis let's spread the knowledge and advancements in cancer treatment! (@cdrjournal)

In this article, @DrEdKim and participants discussed treating a patient with stage IIB lung adenocarcinoma. #lcsm | @cityofhope https://t.co/BhaBy5unKV (@TargetedOnc)

Interesting preclinical study shows MDM2 amplificn occurs in lung adenoca w oncogenic driver mutations (METex14 36%, EGFR 8%, RET 12%, ALK 10%) MDM2 inhibitors + MEKi may be effective here ⁦@charlesrudin⁩ ⁦@JTOonline⁩ ⁦@OncoAlert⁩ #LCSM https://t.co/exkb0goXKE (@DrJNaidoo)

Done✅ In other entities, such as lung adenocarcinoma, screening for brain metastases is standard practice. Given this, why isn't high-risk breast cancer screened for brain metastases as well? (@R_Bodensohn)

Genomic mapping of metastatic organotropism in lung adenocarcinoma: Cancer Cell https://t.co/99qs31CKi1 (@cdanicas)

LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma https://t.co/qbOl2RAmfr (@AndresFCardonaZ)

Interesting case. Suspect this is a mixed histology tumor. Lineage plasticity between lung adenocarcinoma and sclc has increasingly been recognized. @WadeIams team has published a case with de novo KRAS G12C SCLC https://t.co/kqlcxaBB8J and we’ve seen a case in clinic also (@BZhangMD)

STING appears to be ‘stinging’ metastases 🖕👇 ‘STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma' @gary_lyman @OncoAlert (@NicoleKuderer)

STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma | Nature https://t.co/0sC1HzfCrx (@VivekSubbiah)

STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma https://t.co/8m3Op7v7T8 (@weldeiry)

#OpenAccess in @jclinicalinvest by Mariano Barbacid @CNIOStopCancer: Kras oncogene ablation prevents resistance in advanced lung adenocarcinoma https://t.co/DkKbSJLFmx Preclinical study comparing genetic v pharmacological inhibition of mutant KRAS allele on resistance emergence (@Aiims1742)

#uscap2023 Dr. Rojas from the TMP group presenting the use of AI to evaluate lymphocyte infiltrate in lung adenocarcinoma (@vgprieto14)

Back to the office: URL lung adenocarcinoma, no actionable mutations, PD-L1 20%, mediastinal invasion, positive N2 by PET-CT & EBUS (4R, not shown here). Same patient in 2016 after MDT would be considered for definitive chemoradiation and eventually included in PACIFIC trial. (@Tony_Calles)

LKB1-dependent regulation of TPI1 creates a divergent metabolic liability between human and mouse lung adenocarcinoma https://t.co/BPfqsvHQa0 (@weldeiry)

Wow! Humble double-down. My PhD was in molecular biology of lung adenocarcinoma and I know the detailed interactions of EGFR and Ras at the protein level. Do you know how to do a sleeve Lobectomy and bronchial reconstruction? Silly hill to die on. (@Clavikul)

Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival https://t.co/3I9bzLqtlb (@drfeelgood049)

The second cohort is DFCI-OncoPrint cohort. Is TP53 targetable yet? Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma https://t.co/Ppu7PuDkLl https://t.co/QCyrj1om8s (@LeXiuning)

Happy to share our last preprint on how we used knowledge-based mechanistic modeling to predict disease progression with gefinitib in EGFR-mutant lung adenocarcinoma : https://t.co/bNdyWGA5fd @MDuruisseaux (@Claudio_MonT_s)

Small Cell Transformation in a Patient With RET Fusion–Positive Lung Adenocarcinoma on Pralsetinib https://t.co/J2GFUqdviJ (@VivekSubbiah)

In cases of TTF1- adenocarcinoma, presence of hilar/mediastinal lymph nodes endorses the diagnosis of #NSCLC 40% of lung adenocarcinomas is TTF1 negative https://t.co/Xh6waU0go2 (@eliogreg)

KEAP1 mutations (mut) are heterogeneous in lung adenocarcinoma (LUAD). In this study out in @Annals_Oncology we found that clonal KEAP1 mut w/ LOH have unique transcriptomic & immunophenotypic features, and are associated w/ #ICI resistance @OncoAlert https://t.co/RzVIoiV300 1/7 (@BiagioMd)

Clonal somatic LOH of KEAP1 leads to resistance to ICIs in patients with advanced lung adenocarcinoma. We need more predictive biomarkers than PD-L1 to select appropriate patients in the age of IO. https://t.co/UDo10BKKlC @OncoAlert (@yekeduz_emre)

Really interesting OS data from Evan - cis/vin vs erlotinib as adj in stage IIIA EGFR+ lung adenoCa Curves remain widely separate over time despite erlotinib stopping at 2 years. Going to be interesting to see how ADAURA behaves #lcsm @EGFRResisters https://t.co/24kTaXpHfx (@drtclay)

Early Application of #NextGenerationSequencing Identifies Pancreatic Mass as Metastasis From an #EGFR-Mutated Lung Adenocarcinoma: https://t.co/cXMXSoXl0s #targetedtherapy #LCSM #PancSM @SriGaddamMD @DrNickNissen @DrHendifar @jgong15 @ReckampK @DrArsenOsipov @CedarsSinai (@JNCCN)

Preclinical study @jclinicalinvest: Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47 (corollary - KRAS inhibitors diminish “don’t eat me” signal on cancer cell surface). https://t.co/JJozmcr3Jp (@Aiims1742)

Our case report is out #JTOCRR @JTOonline! Here we describe a patient with KRAS G12C-mutated lung adenocarcinoma and untreated brain metastases who achieved significant clinical and radiographical response to #sotorasib. https://t.co/vScFwdEPpV (@chulkimMD)

Dr. Carla Concepcion @columbiacancer speaks about role of lung adenocarcinoma tumor suppressor Smarca4 and subsequent heterogeneity and chromatin states, NKX2.1, and impact on SWI/SNF to bind and open chromatin to shape tumor evolution @ACS_Research Jiler conference (@weldeiry)

Investigators have concluded that TROP-2 plays a significant role in promoting lung adenocarcinoma and could be a novel prognostic biomarker as well as a therapeutic target in the space. @GRSimonMD @MoffittNews #lcsm https://t.co/jhpXE82u4e (@OncLive)

#PostTest Q2️⃣ #TumorBoardTuesday 👉🏽Free CME🔗: https://t.co/0as2gaTcp9 🧐What subsequent tx would you pick for: 50yo👩🏻 🚭 mNSCLC (adenoca, EGFRdel19, PD-L1 70%+) new liver lesions 🫁worsening effusion 6 mos after SRS to 🧠 lesions continued osimertinib (Assume all tx avail) (@n8pennell)

Indeed, this remind me our experience in NSCLC with CTC: Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. @ddemiguelperez @MJOSESERRANO19 @Al3ssandroRusso https://t.co/d1Ba2tfimp (@ChristianRolfo)

102-year-old woman with EGFR+ lung adenocarcinoma in CR with Osi for 3 years. And as if that were not enough, she drives a motorcycle in Bogota!!! (@AndresFCardonaZ)

APOBEC mutagenesis "turned on" in EGFR-mutant osimertinib-resistant lung adenocarcinomas https://t.co/GeRnVoDwp4 @HelenaYu923 @christine_lovly @charlesrudin (@MLadanyi)

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽CME Eval 🔗https://t.co/I3w85MiXJq 🤔@NarjustFlorezMD @shrutipatelmd taught 1L #NSCLC differentiate PD1/PDL1, test your 🧠 with 4❓ 🧐What 1L would YOU pick for a metastatic #NSCLC (adenoca) pt with neg action molecule bio & 54% PDL1 express? (@ShrutiPatelMD)

my dad has a metastatic non-small cell lung adenocarcinoma, Kras g12c, concluded Sotorasib .... the situation is critical ..... (@Na1De)